Moneycontrol PRO
Open App

Cadila: Biosimilars, oncology portfolio hold promise for medium term

The Moraiya plant’s pending USFDA approval is crucial for Cadila’s US ambition

February 04, 2022 / 11:24 AM IST
Cadila: Biosimilars, oncology portfolio hold promise for medium term

Sun Pharma | Subsidiary has received final approval from US FDA for its abbreviated new drug application (ANDA) for generic Amphotericin B Liposome for injection.

PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook

Cadila Healthcare (CMP: Rs 408, Market Cap: Rs 41,738 crore) has reported uninspiring results due to the decline in the COVID portfolio and headwinds from the US business. This challenge is true for most Indian pharma generic players. However, the pertinent question for investors is whether to shun the US-oriented pharma generics altogether or not. Over the last two years, while the balance sheet has been leaner for the whole sector, we believe there is merit in looking at a few...

  • PRO Panorama

    Moneycontrol Pro Panorama | When boring is good news for the Street

    Sep 30, 2022 / 02:25 PM IST

    RBI chooses to stick to the rate hike narrative, markets leap 1,000 points

    Read Now
  • PRO Weekender

    Moneycontrol Pro Weekender | Fighting the Fed 

    Sep 3, 2022 / 10:06 AM IST

    India is bracing for the ripple effect of the frontloading of rate hikes by the US Fed. The question is, can it have the last laugh

    Read Now

To read the full story, Subscribe to Moneycontrol PRO

Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

Already a member? Sign in

Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

50% OFF

What Do You Get

  • Ad free experience

    Experience a non-intrusive navigation and faster response in the ad free mode

  • Sharpest Opinions

    Access to 230+ exclusive stories per month from our editorial and Experts

  • +

    Have a Global edge with access to content from world renowned experts and journalist

  • Actionable Insights

    Access to 40+ weekly investment ideas including 4 daily technical calls

  • Virtual Events

    Exclusive access to live webinars from market experts on trading and investment strategies

  • Newsletters

    Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

Get upto 50% discount on limited period offers